Market Research Hub

New Research Report Offers Insights and Analysis on Hyperuricemia - Pipeline Review, H2 2017

Study covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.


Albany, NY -- (SBWIRE) -- 10/03/2017 -- Market Research Hub recently added a new research publication on hyperuricemia pipeline review, H2 2017 in its research repository. Hyperuricemia is a term that represents high level of uric acid in the blood. There are several symptoms which indicate hyperuricemia condition. Fever, fatigue, chills, kidney stones, problems associated with urination, and joint problems such as tenderness, swelling and reddish joints are few of the symptoms indicating hyperuricemia or high uric acid level. Age, wrong medications, and family history are few of aspects that increase the level of uric acid in human body. There are several treatments that reduce level of uric acid; corticosteroid medication and NSAIDs (non-steroidal anti-inflammatory drugs) are used to control uric acid level in blood.

Request Free Sample Report:

Gist of the Research Report

The research report on hyperuricemia pipeline review delivers exhaustive information on various therapeutics that are being developed for treating metabolic disorder – hyperuricemia. It reflects an in-depth analysis which includes drug target, stage of development, route of administration (RoA), molecule type and mechanism of action (MoA). The research report focuses on descriptive pharmacological action of therapeutics involved in treating hyperuricemia backed up with a comprehensive research along with latest news, past and present developments as well as press releases.

Company Profiling

Pipeline review of hyperuricemia also covers a descriptive analyses of the key players that are involved in the development of therapeutics for hyperuricemia. It also includes projects that are discontinued or dormant. Therapeutics that are under development in companies or universities as well as institutes are described in this review report. Along with this information, the molecules developed in phase III, pre-registration, phase I and phase II plus preclinical stages by companies is also mentioned (1, 1, 4, 1 and 6 respectively). The companies listed in the review report that deal with therapeutic development for hyperuricemia are AstraZeneca Plc, Allena Pharmaceuticals Inc., CymaBay Therapeutics Inc., Nobelpharma Co Ltd., Nippon Chemiphar Co. Ltd., Teijin Pharma Ltd., and Polaris Pharmaceuticals Inc. This research report includes details of the above mentioned companies, such as, their product portfolios, financials, SWOT etc., that assist the reader in analyzing and implementing different strategies to gain competitive edge. The information is gathered using company and university websites, proprietary databases, featured press releases, clinical trial registries, SEC filings, conferences, third party sources that are industry aligned as well as investor presentations. Real time analysis of various aspects is included in the report.

Scope of the Report

The report on pipeline review of hyperuricemia therapeutics under development covers a global snapshot of hyperuricemia in the second half of 2017. Various drug profiles, therapeutics under development that are used to treat hyperuricemia, analysis of projects that were undertaken as well as intelligence on dormant and discontinued projects in line with development of therapeutics, mergers and acquisitions of players present in this industry, and various events and news are included in the hyperuricemia pipeline review, H2 2017 research report.

Browse Full Report with TOC-

Reasons to Invest in the Report

The report on the pipeline review of hyperuricemia delivers value in all angles within the industry. It reflects intelligence on key players, their strategies, financials, as well as product innovations. The report assists the reader to gain edge over the competition by supporting in devising different counter strategies during the timeline. Articulate corrective measures for different pipeline projects is just the tip of the iceberg. The reader can also design and develop out-licensing and in-licensing strategies by identifying key partners, prospects and thus expand scope of their business by detecting highly attractive projects.

Enquire about this Report-

About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH's expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free : 800-998-4852 (US-Canada)
Email :
Website :
Read Industry News at -